Journal
JOURNAL OF CLINICAL INVESTIGATION
Volume 127, Issue 8, Pages 3039-3051Publisher
AMER SOC CLINICAL INVESTIGATION INC
DOI: 10.1172/JCI93182
Keywords
-
Categories
Funding
- National Cancer Institute (NCI) [P01-CA080124]
- NCI [R01-CA126642, R35-CA197743, R01-CA096915]
- NCI/Federal Share Proton Beam Program Income
- NIH [DP2 OD008780, R00 CA137167]
- Department of Defense [W81XWH-10-1-0016]
- Executive Committee on Research Tosteson Fund for Medical Discovery Fellowship
Ask authors/readers for more resources
Current anti-VEGF therapies for colorectal cancer (CRC) provide limited survival benefit, as tumors rapidly develop resistance to these agents. Here, we have uncovered an immunosuppressive role for nonclassical Ly6C(lo) monocytes that mediates resistance to anti-VEGFR2 treatment. We found that the chemokine CX3CL1 was upregulated in both human and murine tumors following VEGF signaling blockade, resulting in recruitment of CX3CR1(+)Ly6C(lo) monocytes into the tumor. We also found that treatment with VEGFA reduced expression of CX3CL1 in endothelial cells in vitro. Intravital microscopy revealed that CX3CR1 is critical for Ly6C(lo) monocyte transmigration across the endothelium in murine CRC tumors. Moreover, Ly6C(lo) monocytes recruit Ly6G(+) neutrophils via CXCL5 and produce IL-10, which inhibits adaptive immunity. Preventing Ly6C(lo) monocyte or Ly6G(+) neutrophil infiltration into tumors enhanced inhibition of tumor growth with anti-VEGFR2 therapy. Furthermore, a gene therapy using a nanoparticle formulated with an siRNA against CX3CL1 reduced Ly6C(lo) monocyte recruitment and improved outcome of anti-VEGFR2 therapy in mouse CRCs. Our study unveils an immunosuppressive function of Ly6C(lo) monocytes that, to our knowledge, has yet to be reported in any context. We also reveal molecular mechanisms underlying antiangiogenic treatment resistance, suggesting potential immunomodulatory strategies to enhance the long-term clinical outcome of anti-VEGF therapies.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available